Procore signs multi-year strategic collaboration agreement with AWS
Karah Herdman Parschauer, a director at Evolus, Inc. (NASDAQ:EOLS), has sold a significant portion of her holdings in the company. According to a recent SEC filing, Parschauer sold 12,888 shares of Evolus common stock on March 12, 2025. The shares were sold at a weighted average price of $12.9939, resulting in a total transaction value of $167,465. The transaction comes as the $833 million market cap company shows strong revenue growth of 32% and maintains a GOOD financial health score, according to InvestingPro data.
Following this transaction, Parschauer continues to hold 32,183 shares of Evolus. The sale was executed in multiple trades at prices ranging from $12.98 to $13.025. This transaction reflects a strategic decision by Parschauer, who holds her shares directly. Notably, analysts maintain a bullish outlook on the stock, with price targets ranging from $20 to $27, suggesting significant upside potential. Get access to 6 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.
In other recent news, Evolus reported its fourth-quarter 2024 financial results, revealing a revenue of $79 million, which exceeded expectations of $76.96 million, despite an earnings per share (EPS) miss of -$0.11 against a forecasted $0.02. The company achieved full-year revenues of $266.3 million, marking a 32% increase from the previous year, driven by strong U.S. product sales. Evolus has set its 2025 revenue guidance between $345 million and $355 million, indicating a projected growth of 30% to 33%, with the newly launched Evolysse product expected to contribute significantly to this growth. Stifel and H.C. Wainwright both maintain a Buy rating on Evolus stock, with price targets set at $25 and $27, respectively, reflecting a positive outlook on the company’s financial trajectory.
The analysts from Stifel highlighted Evolus’s transformation into an aesthetics portfolio company, emphasizing the potential for operational leverage and significant synergies following the launch of new products. H.C. Wainwright’s analyst Douglas Tsao noted the early approval of Evolysse as a positive development that boosts confidence in the company’s ability to meet its projected numbers. Evolus also achieved full-year profitability ahead of schedule, with a positive non-GAAP operating income of $0.3 million for 2024.
The company has expanded its active accounts to over 50% of U.S. accounts and saw record enrollment in its loyalty programs, surpassing 1.1 million participants. Looking forward, Evolus aims for $700 million in revenue by 2028, with a target of 20% non-GAAP operating income margin. The recent FDA approval of new products, Evolise Form and Evolise Smooth, is anticipated to drive future growth, further solidifying Evolus’s position in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.